SAS and Posit Join Forces for Controlled AI in Life Sciences: A New Era of Data Integration
SAS, a leader in data and artificial intelligence, has announced a pivotal partnership with Posit PBC (formerly RStudio) aimed at revolutionizing how life sciences organizations leverage data technologies. This collaboration promises to bring a new level of flexibility, allowing clinical development teams to seamlessly combine regulated clinical research methods with the innovative power of open-source technology.
Overview of the Partnership
The integration plan under this alliance focuses on combining SAS's flagship products, SAS® Viya® and SAS® Clinical Acceleration, with Posit's tools such as Posit Workbench, Positron, Posit Connect, and Posit Package Manager. By merging SAS's sophisticated governance and analytics capabilities with Posit's open-source solutions, this initiative aims to facilitate a more agile approach to clinical data management, enhancing the productivity and compliance required for clinical trials.
Mark Lambrecht, Global Head of Health Care and Life Sciences Solutions at SAS, highlighted that, “Life sciences companies can now achieve the agility of open-source technologies while adhering to the stringent accuracy required for regulated clinical research.” This partnership not only increases the operational flexibility for researchers but also upholds rigorous standards for transparency and governance which are imperative in the regulatory landscape.
Innovative Tools for Clinical Research
At the core of this collaboration lies the SAS Clinical Acceleration, built on SAS Viya’s cloud-native architecture. This platform offers a secure repository for clinical data alongside a dedicated statistical computing environment, combined with AI-driven transformations that prepare clinical research data for submission to regulatory bodies. Posit’s contributions are set to expand these functionalities further, providing users with a secure environment to integrate open-source technologies within a managed enterprise framework.
Eric Pite, Senior Vice President of Product and Strategy at Posit, shared the demands from clinical teams for better use of R and Python without compromising the control mechanisms they rely on via SAS. He elaborated on how programmers can now write both SAS and R code simultaneously in Positron, allowing SAS Viya to execute SAS code under controlled user permissions, ultimately providing tailored support for various clinical workflows.
Benefits of Collaboration
The key advantage of this partnership lies in its promise to allow users to work within version-controlled R environments while maintaining crucial oversight on dependency and interoperability matters linked with SAS Clinical Acceleration. This integrated approach enables data scientists and developers to operate in a cohesive environment across SAS, R, Python, and SQL, boosting productivity and innovation.
Dilip Raghunathan from Regeneron emphasized the significance of this development, stating that, “Working with both R and SAS within the same workflow previously led to cumbersome workarounds and data duplication.” He stated that the new collaboration allows programmers to write seamlessly in one session under their access rights, benefitting from AI support that functions within the same controls.
Meet Us at PHUSE EU Connect
Both SAS and Posit will be present at the upcoming PHUSE EU Connect event from November 15 to 18 in Glasgow. Attendees can visit Posit at booth 43 and SAS at booth P3. This event provides an excellent opportunity for industry professionals to learn more about how these companies are striving to innovate within the life sciences field through effective data use and advanced AI applications.
In summary, the partnership between SAS and Posit marks a significant advancement in the life sciences industry, integrating open-source agility with strict regulatory compliance. Organizations can expect enhanced collaborative opportunities that bring together the strengths of AI, data management, and open-source technologies, driving forward the clinical research landscape.
With decades of leading innovations and expert domain knowledge, SAS maintains its commitment to empowering organizations with data-driven insights. For more information, visit their websites or contact them directly for any inquiries. This partnership not only exemplifies the forward-thinking strategies of both organizations but sets a benchmark in the realm of data and AI integration in clinical research.